MOYOM Biotech Lands Cathay Capital Funding for Global Expansion
Image
Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.
Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation
The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.